{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:57:43Z","timestamp":1786985863825,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.cct.2016.10.006","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T14:01:36Z","timestamp":1477058496000},"page":"54-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine"],"prefix":"10.1016","volume":"52","author":[{"given":"Alain","family":"Luxembourg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne K.","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Nygard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misoo C.","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Brooke","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Radley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Saah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2016.10.006_bb0005","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cct.2016.10.006_bb0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.cct.2016.10.006_bb0015","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1016\/j.ejca.2013.06.033","article-title":"Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva","volume":"49","author":"de Sanjose","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cct.2016.10.006_bb0020","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.ejca.2014.07.018","article-title":"Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samples","volume":"50","author":"Alemany","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cct.2016.10.006_bb0025","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.cct.2016.10.006_bb0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.28963","article-title":"Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide","volume":"136","author":"Alemany","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cct.2016.10.006_bb0035","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related disease","volume":"30S","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cct.2016.10.006_bb0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.10.006_bb0045","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.10.006_bb0050","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.10.006_bb0055","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.10.006_bb0060","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.cct.2016.10.006_bb0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1740774514552110","article-title":"A seamless phase IIB\/III adaptive outcome trial: design rationale and implementation challenges","volume":"12","author":"Chen","year":"2015","journal-title":"Clin. Trials."},{"key":"10.1016\/j.cct.2016.10.006_bb0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cct.2015.02.009","article-title":"Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine","volume":"42","author":"Luxembourg","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.cct.2016.10.006_bb0075","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/21645515.2015.1012010","article-title":"Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine","volume":"11","author":"Luxembourg","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.cct.2016.10.006_bb0080","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1542\/peds.2014-3745","article-title":"Immunogenicity and safety of a 9-valent HPV vaccine","volume":"136","author":"Van Damme","year":"2015","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.cct.2016.10.006_bb0085","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/JCM.00236-10","article-title":"Comparison of real-time multiplex human papillomavirus PCR assay with INNO-LiPA HPV genotyping extra assay","volume":"49","author":"Else","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.cct.2016.10.006_bb0090","doi-asserted-by":"crossref","unstructured":"Roberts CC, Swoyer R, Bryan JT et al. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection. J. Clin. Microbiol. 2011; 49(5): 1899\u2013906. 10.1128\/JCM.00235-10 (May)","DOI":"10.1128\/JCM.00235-10"},{"key":"10.1016\/j.cct.2016.10.006_bb0095","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1097\/PAS.0b013e318058a544","article-title":"Longitudinal evaluation of interobserver and intraobserver agreement of cervical intraepithelial neoplasia diagnosis among an experienced panel of gynecologic pathologists","volume":"31","author":"Cai","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.cct.2016.10.006_bb0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2014part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cct.2016.10.006_bb0105","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.vaccine.2006.06.018","article-title":"Chapter 5: updating the natural history of HPV and anogenital cancer","volume":"24","author":"Moscicki","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.cct.2016.10.006_bb0110","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.cct.2016.10.006_bb0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3; a restrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cct.2016.10.006_bb0120","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.4161\/hv.29205","article-title":"Development of a human papillomavirus competitive immunoassay for nine HPV types","volume":"10","author":"Roberts","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.cct.2016.10.006_bb0125","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1080\/03610929808832160","article-title":"Exact power and sample size for vaccine efficacy studies","volume":"27","author":"Chan","year":"1998","journal-title":"Commun. Stat. Theory Method"},{"key":"10.1016\/j.cct.2016.10.006_bb0130","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.vaccine.2011.11.097","article-title":"Introduction of human papillomavirus vaccination in Nordic countries","volume":"30","author":"Sander","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cct.2016.10.006_bb0135","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cct.2016.10.006_bb0145","series-title":"Human Papillomavirus 9-Valent Vaccine (Recombinant, Adsorbed)","article-title":"Summary of the risk management plan (RMP) for Gardasil 9","year":"2016"},{"key":"10.1016\/j.cct.2016.10.006_bb0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1467-985X.00256","article-title":"A review and discussion of prospective statistical surveillance in public health","volume":"166","author":"Sonesson","year":"2003","journal-title":"J. R. Stat. Soc. A. Stat. Soc."},{"key":"10.1016\/j.cct.2016.10.006_bb0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/00224065.2006.11918593","article-title":"The use of control charts in health care and public-health surveillance","volume":"38","author":"Woodall","year":"2006","journal-title":"J. Qual. Technol."},{"key":"10.1016\/j.cct.2016.10.006_bb0160","author":"Kjaer"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416301781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416301781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T18:28:21Z","timestamp":1568485701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714416301781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":31,"alternative-id":["S1551714416301781"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2016.10.006","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2016.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}